NASDAQ:TXMD TherapeuticsMD (TXMD) Stock Price, News & Analysis → Warren Buffett, Jeff Bezos, Michael Bloomberg, & 48 Members of Congress Are Buying ONE Sector… (From InvestorPlace) (Ad) Free TXMD Stock Alerts $2.22 +0.09 (+4.23%) (As of 05/31/2024 ET) Add Compare Share Share Today's Range$2.10▼$2.2250-Day Range$1.86▼$2.3252-Week Range$1.84▼$4.50Volume10,453 shsAverage Volume12,252 shsMarket Capitalization$25.60 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Ad The Freeport SocietyBiden Nomination CANCELED?The Hill just published that Joe Biden has received enough delegates to…“clinch the Democratic presidential nomination and all but guaranteeing he will face off against former President Trump again in November.” Why is he all BUT guaranteed the Democratic nomination, in their words?I believe I have the terrifying answer right here. About TherapeuticsMD Stock (NASDAQ:TXMD)TherapeuticsMD, Inc. operates as a pharmaceutical royalty company in the United States. It has a license agreement with Mayne Pharma to commercialize the IMVEXXY, BIJUVA, and ANNOVERA prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brand names. The company sells its prescription pharmaceutical products and prenatal vitamin products through wholesale distributors and retail pharmacy distributors. TherapeuticsMD, Inc. was founded in 2008 and is headquartered in Boca Raton, Florida.Read More TXMD Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart TXMD Stock News HeadlinesJune 1 at 5:58 AM | americanbankingnews.comTherapeuticsMD (NASDAQ:TXMD) Receives New Coverage from Analysts at StockNews.comMay 25, 2024 | americanbankingnews.comTherapeuticsMD (NASDAQ:TXMD) Earns Hold Rating from Analysts at StockNews.comMay 15, 2024 | finance.yahoo.comTherapeuticsMD, Inc. (TXMD) Stock Price, News, Quote & History - Yahoo FinanceMay 10, 2024 | investorplace.comTXMD Stock Earnings: TherapeuticsMD Reported Results for Q1 2024May 10, 2024 | businesswire.comTherapeuticsMD Announces First Quarter 2024 Financial ResultsMarch 29, 2024 | businesswire.comTherapeuticsMD Announces Full Year 2023 Financial ResultsMarch 12, 2024 | msn.com25 Countries With Highest Abortion RatesMarch 10, 2024 | sg.finance.yahoo.comTherapeuticsMD, Inc. (TXMD) stock historical prices & data – Yahoo FinanceDecember 29, 2023 | morningstar.comTherapeuticsMD Inc TXMDNovember 15, 2023 | nasdaq.comDaily Markets: Today Brings Producer Prices, Retail Sales DataNovember 14, 2023 | marketwatch.comTherapeuticsMD to Consider Strategic AlternativesNovember 14, 2023 | msn.comTherapeuticsMD exploring strategic alternatives for companyNovember 14, 2023 | finance.yahoo.comTherapeuticsMD Announces Third Quarter 2023 Financial ResultsOctober 4, 2023 | bizjournals.comBoca Raton-based prescription service announces layoffs, says a third of workforce could be cutSeptember 20, 2023 | marketwatch.comTherapeuticsMD Inc. stock falls Wednesday, underperforms marketAugust 15, 2023 | marketwatch.comTherapeuticsMD Inc. stock outperforms market despite losses on the dayAugust 14, 2023 | finance.yahoo.comTherapeuticsMD Announces Second Quarter 2023 Financial ResultsAugust 9, 2023 | finance.yahoo.comMicron Biomedical Appoints Brian Bernick, MD as Chairman of Its Board of DirectorsJuly 5, 2023 | marketwatch.comTherapeuticsMD Inc. stock underperforms Wednesday when compared to competitorsJuly 4, 2023 | thestreet.comTherapeuticsMD Rejected by FDA, Delay Could Be FatalMay 23, 2023 | seekingalpha.comTherapeuticsMD: From Fallen And Forgotten To Cash CowMay 15, 2023 | finance.yahoo.comTherapeuticsMD Announces First Quarter 2023 Financial ResultsMay 10, 2023 | marketwatch.comTherapeuticsMD Inc. stock falls Tuesday, underperforms marketMay 10, 2023 | marketwatch.comTherapeuticsMD Inc. stock rises Wednesday, still underperforms marketMay 3, 2023 | marketwatch.comTherapeuticsMD Inc. stock falls Monday, underperforms marketSee More Headlines Company Calendar Last Earnings5/10/2024Today6/01/2024Next Earnings (Estimated)8/12/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:TXMD Previous SymbolNYSEMKT:TXMD CUSIPN/A CIK25743 Webwww.therapeuticsmd.com Phone(561) 961-1900Fax561-431-3389Employees1Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-10,280,000.00 Net MarginsN/A Pretax Margin-520.52% Return on Equity-21.15% Return on Assets-13.08% Debt Debt-to-Equity RatioN/A Current Ratio1.78 Quick Ratio1.78 Sales & Book Value Annual Sales$1.30 million Price / Sales19.69 Cash FlowN/A Price / Cash FlowN/A Book Value$2.49 per share Price / Book0.89Miscellaneous Outstanding Shares11,530,000Free Float11,394,000Market Cap$25.60 million OptionableOptionable Beta1.07 Key ExecutivesGovernor Thomas G. Thompson (Age 82)Executive Chairman Comp: $160kMr. Marlan D. Walker J.D. (Age 49)Chief Executive Officer Comp: $661.42kMr. Joseph A. Ziegler (Age 50)Principal Financial & Accounting Officer Comp: $84.64kMr. Robert G. Finizio (Age 53)Co-Founder Comp: $7.51kMr. Douglas SteelmanVice President of Market AccessKey CompetitorsOsmotica PharmaceuticalsNASDAQ:OSMTLifeVantageNASDAQ:LFVNProPhase LabsNASDAQ:PRPHAssertioNASDAQ:ASRTTiziana Life SciencesNASDAQ:TLSAView All CompetitorsInsiders & InstitutionsGabelli Funds LLCSold 17,000 shares on 5/15/2024Ownership: 0.104%Prosperity Consulting Group LLCBought 24,500 shares on 5/1/2024Ownership: 0.212%Marlan D WalkerSold 14,500 sharesTotal: $33,495.00 ($2.31/share)View All Insider TransactionsView All Institutional Transactions TXMD Stock Analysis - Frequently Asked Questions Should I buy or sell TherapeuticsMD stock right now? 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for TherapeuticsMD in the last year. There are currently 1 hold rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" TXMD shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in TXMD, but not buy additional shares or sell existing shares. View TXMD analyst ratings or view top-rated stocks. How have TXMD shares performed in 2024? TherapeuticsMD's stock was trading at $2.25 on January 1st, 2024. Since then, TXMD shares have decreased by 1.3% and is now trading at $2.22. View the best growth stocks for 2024 here. Are investors shorting TherapeuticsMD? TherapeuticsMD saw a drop in short interest in May. As of May 15th, there was short interest totaling 39,300 shares, a drop of 23.2% from the April 30th total of 51,200 shares. Based on an average daily volume of 22,800 shares, the short-interest ratio is currently 1.7 days. Currently, 0.4% of the company's shares are sold short. View TherapeuticsMD's Short Interest. When is TherapeuticsMD's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, August 12th 2024. View our TXMD earnings forecast. How were TherapeuticsMD's earnings last quarter? TherapeuticsMD, Inc. (NASDAQ:TXMD) released its quarterly earnings data on Friday, May, 10th. The company reported ($0.07) EPS for the quarter. The company had revenue of $0.31 million for the quarter. When did TherapeuticsMD's stock split? TherapeuticsMD's stock reverse split before market open on Monday, May 9th 2022. The 1-50 reverse split was announced on Monday, May 9th 2022. The number of shares owned by shareholders was adjusted after the market closes on Monday, May 9th 2022. An investor that had 100 shares of stock prior to the reverse split would have 2 shares after the split. What other stocks do shareholders of TherapeuticsMD own? Based on aggregate information from My MarketBeat watchlists, some companies that other TherapeuticsMD investors own include OPKO Health (OPK), Verastem (VSTM), Teva Pharmaceutical Industries (TEVA), Inovio Pharmaceuticals (INO), NVIDIA (NVDA), Sorrento Therapeutics (SRNE), Gilead Sciences (GILD), Cleveland-Cliffs (CLF), Novavax (NVAX) and Micron Technology (MU). Who are TherapeuticsMD's major shareholders? TherapeuticsMD's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Prosperity Consulting Group LLC (0.21%) and Gabelli Funds LLC (0.10%). Insiders that own company stock include Brian Bernick, Cooper C Collins, Gail K Naughton, James Darecca, Marlan D Walker, Michael C Donegan, Paul Bisaro, Rubric Capital Management Lp and Tommy G Thompson. View institutional ownership trends. How do I buy shares of TherapeuticsMD? Shares of TXMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:TXMD) was last updated on 6/1/2024 by MarketBeat.com Staff From Our PartnersDems have chosen Biden replacement?Paradigm PressWarren Buffett, Jeff Bezos, Michael Bloomberg, & 48 Members of Congress Are Buying ONE Sector…InvestorPlaceTrump’s Gift Could Unleash $51 Billion in New WealthWealthpin ProShocking: One AI startup's revenue could surge 4,735%Manward PressBill Clinton Backing Biden Replacement???The Freeport SocietyNvidia has Apple and Microsoft within striking rangeWeiss RatingsDon’t buy a single NVIDIA share before you see this...Behind the MarketsExposed: 10 CENT Crypto to Explode May 20th?True Market Insiders Adding Choose a watchlist: Watchlist My Default Watchlist Adding TherapeuticsMD, Inc. You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.